For patients with EGFR-mutant NSCLC who progress on osimertinib, do you repeat tumor molecular profiling?   

If so do you favor repeat tumor biopsy or cfDNA?

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Kettering Cancer Center
Tissue biopsy continues to be the gold standard an...
Medical Oncologist at Siri Onclogy and hematology Infusion Service
This is one space, like many others, do not do the...
Medical Oncologist at West Virginia University Cancer Institute
Agree. In EGFR at progression with osimertinib as ...
Sign in or Register to read more